^
Association details:
| Biomarker: | IL2-L |
|---|---|
| Cancer: | Follicular Lymphoma |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
BENDAMUSTINE DOSE, TREATMENT CYCLES, AND THE IMPACT OF SOLUBLE IL-2R AND LDH VALUES ON BENDAMUSTINE PLUS RITUXIMAB TREATMENT FOR PATIENTS WITH FOLLICULAR LYMPHOMA
Published date:
06/12/2020
Excerpt:
Bendamustine plus rituximab therapy (BR) is one of the mainstays of therapy for patients with follicular lymphoma (FL)….survival benefits were observed in the OS of the sIL-2R-low group (P = 0.0226, hazard ratio [HR]: 0.2744, 95% confidence interval [CI]: 0.07657–0.8156).
Secondary therapy:
bendamustine
